Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three- and nine-month periods ending September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2008 were approximately $3,501,000 versus $3,520,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.4 million) or ($0.04) per share. This compares with a net loss of approximately ($3.0 million), or ($0.04) per share for the same period last year.

Revenues for the nine months ended September 30, 2008 were approximately $3,501,000 versus $3,520,000 for 2007. Reported net loss for the first nine months of 2008 was ($21.3 million), or ($0.26) per share as compared to ($18.6 million) or ($0.23) per share for 2007. As of September 30, 2008, EntreMed had cash and short-term investments of approximately $28 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "We have estimated that the royalty revenue from sales of Thalomid(R) for the 3rd quarter will be $3.5 million and we expect royalty revenue for the year to increase over 2007 with Celgene's acquisition of Pharmion Corporation. Research and development expenses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earlier in the year to discontinue the use of Panzem in oncology, but also impacted by a decreasing number of patients being treated with MKC-1 related to Phase 2 trials ini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Spartan Bioscience announced today ... CYP2C19 System . It detects CYP2C19 genetic mutations in ... , The Spartan RX CYP2C19 System is the first ... approved in Canada. Due to the system’s ease of ... used by healthcare professionals such as doctors, nurses, pharmacists, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... will present a company overview at the Nomura Biotechnology Conference ... Boston, MA. A live ... & Media" section of the Company,s website, www.isispharm.com .  ... 48 hours and will be archived for a limited time. ...
(Date:10/30/2014)...  Regado Biosciences, Inc. (Nasdaq: RGDO ), ... and live audio webcast on Thursday, November 6, 2014, ... 2014 financial results. Interested participants and investors ... for domestic callers or (412) 902-4276 for international callers. ... investor relations section of the Regado website at ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... siRNA expression construct into a variety of mammalian cells ... , ... Modified CMV promoter efficiently expresses hairpin siRNAs , ... , Efficient delivery of siRNA or an siRNA , ...
... In the past few years, interest in the , ... small RNA molecules has , ... interrelated lines of research. In one, small double-stranded , ... (siRNAs) have been , ...
... Dicer and Escherichia coli RNase III can be used ... cleave long dsRNA, producing siRNA cocktails that are , ... endoribonuclease that contains RNase III domains and is the , ... of long dsRNAs to siRNA in the , ...
Cached Biology Technology:Delivering siRNA Using Adenoviral Vectors 2Delivering siRNA Using Adenoviral Vectors 3Delivering siRNA Using Adenoviral Vectors 4Detecting miRNA & siRNA 2Detecting miRNA & siRNA 3Detecting miRNA & siRNA 4Detecting miRNA & siRNA 5Detecting miRNA & siRNA 6Detecting miRNA & siRNA 7Detecting miRNA & siRNA 8Detecting miRNA & siRNA 9Dicer vs. RNase III for Preparation of siRNA Cocktails 2Dicer vs. RNase III for Preparation of siRNA Cocktails 3
(Date:10/29/2014)... food, but they also need protection from its harmful rays, ... molecules in plants that shields them from sun damage. Now, ... Chemical Society , one team reports on the mechanics of ... colleagues at Purdue University note that the harsh ultraviolet radiation ... plant DNA and, as a result, hinder plant growth. ...
(Date:10/29/2014)... nanoparticles is all the rage. Thousands of scientists worldwide ... of whether titanium dioxide nanoparticles from sun creams can ... carbon nanotubes from electronic products are as hazardous for ... nanoparticles in food can get into the blood via ... research funds are flowing – and the number of ...
(Date:10/29/2014)... – As bodies decompose, their types and numbers ... they provide could mean the difference between a ... State University is using a more than $866,000 ... death-scene investigators examine these changing populations. The microbial ... location of death, gender, race, socioeconomic relations and ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3MSU partners with Detroit to investigate death scenes 2
... 2010 - Novocure reported today that patients with advanced ... in survival time when tumor treating fields (TTF) therapy ... outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, ... center in Switzerland, presented the data at the European ...
... have reported direct evidence that taking up smoking results in ... results were reported at the 35th Congress of the European ... link between smoking and cancer has been established for decades, ... Institute of Cancer Studies, Birmingham, who presented the results. Smoking ...
... at Chicago College of Medicine have found how gene expression ... unusual types of breast tumors. Their findings may offer new ... 8 issue of the Journal of Biological Chemistry, ... Approximately 70 percent of breast cancers express the estrogen receptor. ...
Cached Biology News:Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer 2Study reveals cancer-linked epigenetic effects of smoking 2Clue to unusual drug-resistant breast cancers found 2
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: